Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the Asia Pacific induced pluripotent stem cells market. In addition, complete analysis of changes on the Asia Pacific induced pluripotent stem cells market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Asia Pacific economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The growth of the market is primary driven owing to better regulatory support through encouraging government policies and increasing awareness among the public. Adding to that, the Asia-Pacific stem cells market is invested in various research organizations and developments of the stem cell industry. Innovation and implementation of multiple technologies and rising population continuously in the region enhance the markets demand. The increased quality of differentiated cells resulting from efficient manufacturing as a result of partnerships is anticipated to expand the stem cell market's potential possibilities. moreover, during the projection period, the market would benefit from integrating several sectors such as materials, devices, chemical compounds, and biologics. In addition, favorable regulatory frameworks in emerging regions are projected to create substantial development possibilities for domestic and foreign companies in the stem cell manufacturing industry.
Growing investment in basic level research, especially by research organizations and academic institutes in the last few years has led to an increased understanding of the fundamental pathways through which induced pluripotent stem cells implicated in disease development are either up or down-regulated. This leads to more questions about how biology works, the cause of the diseases and potential diagnoses and treatments. Induced pluripotent stem cells display a particular gene expression signature that is similar to that of embryonic stem cells and exhibit both pluripotency and the capacity of self-renewal. In the recent past, the complexity of products requested by researchers has grown and this suggests improvement in understanding of the basic pathways and discovery of some new pathways. It is important for manufacturers of research products to keep up with the latest developments to cater to the ever-changing requirements of the life sciences industry.
Stem cell research is attracting wide attention as a promising and fast-growing field in Asia Pacific, as it is worldwide. Many countries in the region have defined Regenerative Medicine as a research priority and a focus of investment. This field generates not only opportunities but also regulatory, technical and operative challenges. Asia Pacific is a fast-growing region conscious of the relevance of stem cell research for the development of Regenerative Medicine, which we think will play a major role in healthcare.
Factors like high cost associated with the reprograming of cells, ethical issues and lengthy processes are impeding the induced pluripotent stem cells market growth. Low efficiency, potential tumour risk and incomplete programming are added factors limiting induced pluripotent stem cells market growth.
Stem cell therapy comprises a modern technology whose aim is to substitute damaged cells with healthy new ones. Cells are rendered dysfunctional due to any number of factors such as aging, disease, genetic modification, injury. Nowadays, Stem cell therapies are providing substantial benefit to patients suffering a wide range of diseases such as cancer, non-cancer, neuronal disease, diabetes and injuries such as brain trauma and spinal cord injuries. It is well established and rapidly growing in developed country however in developing country, there are several challenges which is shielding the booming of this therapy. Owing to that, it is expected to eventually remove these challenges to create the fresh environment of modern stem cell therapeutic medicine.
The report provides in-depth analysis of Asia Pacific induced pluripotent stem cells market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. With increasing demand for various induced pluripotent stem cells in various applications has led the increasing demand for market and is expected to witness the growth at a specific CAGR from 2022-2028.
_Market.jpg)
The Asia Pacific induced pluripotent stem cells market comprises of different market segment like Derived Cell Type, Product, Processes, Application, End User and Country.
The various derived cell types comprised in the reports are hepatocytes, fibroblasts, keratinocytes and amniotic cells. The fibroblasts segment is likely to witness the fastest growth during the forecast period. Dermal fibroblasts are also one of the cells types from which induced pluripotent stem cells can be derived. Introduction of certain cellular factors converts human fibroblasts to cells with pluripotent potential, termed induced pluripotent stem cells. Induced pluripotent stem cells can then be induced to differentiate using various differentiation programs. Induced pluripotent stem cells have significant implications for disease therapy: they can be differentiated into multiple lineages and are derived from adult tissue, so are not immunoreactive.
The different products comprised in the Asia Pacific induced pluripotent stem cells market is instruments/devices, automated platforms, consumable and kits and services. The instruments/devices have the potential to help in induced pluripotent stem cells generation by regulating the kinetics of reprogramming factor delivery. A considerable number of players are offering instruments/devices under this segment. For example, Lonza offers Nucleofector transfection technology for efficient transfection of neurons, stem cells, primary cells, and cell lines. The company offered 4-D Nucleofector X Unit and 4D- Nucleofector Y Unit. 4-D Nucleofector X Unit helps with the nucleofection process of different cell numbers in different formats.
The various processes comprise in the Asia Pacific induced pluripotent stem cells market are automated and manual. Increasing demand for reproducible large-scale stem cell and differentiated progeny production, with minimum variation, propels the demand for automation platforms. Several countries have started initiatives for induced pluripotent stem cells line collection to facilitate studies of numerous conditions, including diabetes and cardiovascular and neurodegenerative diseases. Several of these initiatives plan to use automated systems to achieve their goal.
Based on application, the Asia Pacific induced pluripotent stem cells market is segmented into drug development and discovery, toxicity screening and regenerative medicine. The toxicity screening is anticipated to witness the fastest growth during the forecast period. The development of human-induced pluripotent stem cell–derived cardiomyocytes has opened a new era to address the challenge of improving drug-induced cardiotoxicity prediction. Human iPSC-CMs can be generated from individuals with diverse genetic backgrounds and varying disease status, which provides unique opportunities to assess drug-induced cardiotoxicity at the population level, ultimately, realizing personalized cardiac safety prediction and permitting mechanistic insights into genetic predisposition of drug-induced cardiotoxicity at the molecular and cellular levels.
The various end users comprised in the Asia Pacific induced pluripotent stem cells market are hospitals, research laboratories and academic research. The research laboratories segment is likely to witness fastest growth during the forecast period. A research institute, research center or research center is an establishment founded for doing research. Research institutes are specialized in basic research or may be oriented to applied research. Although the term often implies natural science research, there are also many research institutes in the social science as well especially for sociological and historical research purposes.
The Asia Pacific induced pluripotent stem cells market report analyses various countries such as China, India, Japan, Australia and South Korea. The China is anticipated to dominate the market in 2021. Followed by India and Japan. The large share of the China market is attributed to the rising incidence of cancer and growing research activity in cancer and stem cells. The rising investment in pharmaceutical R&D is also boosting growth of induced pluripotent stem cells market.
The competitive landscape analysis of Asia Pacific induced pluripotent stem cells market is certainly based range of market players operating in the healthcare market with increasing demand for production of induced pluripotent stem cells market. Besides, number of market players offered wide range of products for different application in various geographic locations. The market has major competitive analysis based on new product launches as well as other developments.
The key players studied in market are Fujifilm Holding Corporation, Astellas Pharma Inc., Fate Therapeutics, Inc., Bristol-Myers Squibb Company, ViaCyte, Inc., Celgene Corporation, Aastrom Biosciences, Inc., Acelity Holdings, Inc., StemCells, Inc., Japan Tissue Engineering Co. Ltd. and Organogenesis Inc. among others.
June 2021: Thermo Fisher Scientific Inc. announced that it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company footprints in global market and leading to upsurge company growth in the upcoming years.
June 2020: The LumaCyte collaborated with Catalent who are the global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. This collaboration aided in expanding the company stem cell technology product Radiance and its application.
Induced pluripotent stem cells hold tremendous clinical potential to transform the entire therapeutic landscape by offering treatments for various medical conditions and disorders. These cells are derived from somatic cells like blood or skin cells that are genetically reprogrammed into embryonic stem cell-like state for developing an unlimited source of a diverse range of human cells for therapeutic applications. Moreover, increasing awareness about stem cells and associated research, potential clinical applications and rising financial assistance by governments and private key players are expected to contribute significantly to the market expansion. The induced pluripotent stem cells market technique is likely to find extensive adoption in the pharmaceutical industry for developing efficient cell sources like induced pluripotent stem cells-derived functional cells to support drug screening and toxicity testing.
1) What are the drivers for induced pluripotent stem cells market?
The key driving factors of the market are as ability to make any cell or tissue the body might need coupled with government and private sectors are sectors are increasing funding and rising industry that focuses on different research work.
2) Which is the leading application segment for induced pluripotent stem cells market?
Drug development and discovery segment has accounted the major market share, and is expected to witness the growth at highest pace during the forecast period.
3) Which region is gaining majority of market share during the forecast period (2022-2028)?
China is expected to gain major market share during the forecast period (2022-2028).
